Akero Therapeutics Stock (NASDAQ:AKRO)


ForecastChart

Previous Close

$46.00

52W Range

$21.34 - $58.40

50D Avg

$46.95

200D Avg

$44.82

Market Cap

$3.72B

Avg Vol (3M)

$1.05M

Beta

-0.29

Div Yield

-

AKRO Company Profile


Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

69

IPO Date

Jun 20, 2019

Website

AKRO Performance


Peer Comparison


TickerCompany
GOSSGossamer Bio, Inc.
ETNB89bio, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
ALECAlector, Inc.
CABACabaletta Bio, Inc.
STOKStoke Therapeutics, Inc.
PLRXPliant Therapeutics, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks